's () Sean Hall tells Proactive that the company is building a cannabis-based drug that is the size of a nanoparticle.
Hall adds that the company is currently intent on marketing the product in around 18 countries, including the EU, the US, Canada, and Australia.
Hall also says that the firm is currently talking to several pharmaceutical firms, two of which are of "significant note".
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Medlab Clinical Ltd named herein, including the promotion by the Company of Medlab Clinical Ltd in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE